Morbidity vs mortality as an endpoint in the ICU setting Newsletter Article 17 February 2013 Pages: 2 - 2
Pharmacoeconomics of key importance in formulary decision-making Duska Franic Newsletter Article 17 February 2013 Pages: 3 - 4
More arguments in favour of Hep A and typhoid vaccination Newsletter Article 17 February 2013 Pages: 4 - 4
Determine the cost effectiveness of prophylactic fluconazole Newsletter Article 17 February 2013 Pages: 5 - 5
Enoxaparin a good choice for patients with nephrotic syndrome Newsletter Article 17 February 2013 Pages: 5 - 5
Decrease drug administration frequency to reduce expenditure Newsletter Article 17 February 2013 Pages: 6 - 6
Can nondrug interventions reduce cholesterol levels effectively? Newsletter Article 17 February 2013 Pages: 7 - 7
Investigating use of cardiovascular agents in primary care practices Newsletter Article 17 February 2013 Pages: 8 - 8
Looking at predictors of cost-related outcomes in neonates Newsletter Article 17 February 2013 Pages: 9 - 9
Blood cell reinfusion vs BMT in the treatment of cancer Newsletter Article 17 February 2013 Pages: 9 - 10
A cost-effective intervention programme for hypertension Newsletter Article 17 February 2013 Pages: 10 - 10
Felodipine combination therapy preferred in hypertension Newsletter Article 17 February 2013 Pages: 11 - 12
Lisinopril improves QOL in patients with hypertension Newsletter Article 17 February 2013 Pages: 13 - 13
Integrity of Canada’s healthcare system challenged Newsletter Article 17 February 2013 Pages: 15 - 15
‘Reasonable pricing’ clause for AIDS drugs may be dropped Newsletter Article 17 February 2013 Pages: 15 - 15